Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Conclusions

In this final episode of OncChats: Moving the Needle in Undifferentiated Pleomorphic Sarcoma, the following experts highlight key takeaways from the Stand Up to Cancer SARC 032 study (NCT03092323) evaluating pembrolizumab (Keytruda) in patients with soft tissue sarcoma and underscore the importance of multidisciplinary care at specialized sarcoma centers:

• J. Dominic Femino, MD, an orthopaedic surgeon with Keck Medicine of USC and chief of the USC Musculoskeletal Oncology Center
• Lee Zuckerman, MD, an orthopaedic surgeon with Keck Medicine of USC
• Mark Agulnik, MD, a medical oncologist with the USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC
• Andrew Lim, MD, a radiation oncologist with Keck Medicine of USC

Femino: In conclusion, I’d just like to summarize some of the key points that we learned about today. So, this Stand Up to Cancer SARC 032 study showed a significant improvement in disease-free survival at 2 years with the addition of neoadjuvant and adjuvant pembrolizumab [Keytruda] to preoperative radiation therapy and wide [excision] surgery for high-risk localized UPS of the extremities. And number two, it represents a promising new collaborative treatment strategy for these patients. Number three, this trial exhibits the benefits of multidisciplinary treatment for soft tissue sarcomas and the importance of treatment at specialized sarcoma centers, such as University of Southern California [USC].

I would like to thank the expert panel from the USC Sarcoma Program, Drs Agulnik, Hu, Zuckerman, and Lim, and thank you to OncLive for providing the platform to bring the global oncology community together. We hope you have found today’s OncChats informative and helpful for the care of your [patients with] sarcoma. For further information about the USC Sarcoma Program, please contact us through our website and phone number. Thank you very much.